[Extracorporeal membrane oxygenation (ECMO): an infection control perspective]

Rev Chilena Infectol. 2021 Oct;38(5):622-633. doi: 10.4067/s0716-10182021000500622.
[Article in Spanish]

Abstract

The advent of SARS-CoV-2 disease in 2020 confronts us with a growing and exponential increase in patients at life risk due to catastrophic and multisystemic respiratory failure in need of extracorporeal membrane oxygenation (ECMO) to survive. This has generated in our country the establishment of ECMO treatment Units in hospitals where it was not carried out before or was carried out as part the interventions in Intensive Care Units (ICU), becoming a new challenge to the infection control and prevention programs. Given that at the time of writing this document there are no specific national regulations that refer to this issue, an approach is proposed for the prevention control and surveillance of nosocomial acquired infections in ECMO patients. A review of the specific risks to which these patients are exposed is presented, defining which prevention measures are required, proposing a specific bundle for installation and maintenance, as well as guidance regarding antibioprophylaxis and suggesting which infectious events to monitor.

Publication types

  • Review

MeSH terms

  • COVID-19*
  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Humans
  • Infection Control
  • Intensive Care Units
  • SARS-CoV-2